Pfizer’s newest range of biosimilars are set to significantly undercut Roche’s ‘best-selling’ Avastin, Herceptin, and Rituxan on pricing. What will be the impact on Roche’s market share?

Pfizer has planned the launch of its biosimilar competitors in the U.S. to Roche’s cancer drugs, Avastin, Herceptin, and Rituxan, at significantly discounted prices, in comparison to the originators.

Experts have noted that the launch of these medicines can lead to substantial savings to the U.S. healthcare system, as Pfizer proposed the lowest list price for the biosimilars of Roche’s big sellers.

At the end of 2019, Pfizer’s Avastin (bevacizumab) biosimilar, Zirabev, was marketed at $61.34 per 10mg, representing a 23% discount compared with the original product. While Ruxience, Pfizer’s biosimilar of Roche’s Rituxan (rituximab), has launched at a cost of $71.68 per 10 mg, hitting the market at a 24% discount.

Additionally, Pfizer plans to launch a biosimilar version of Roche’s Herceptin (trastuzumab), under the brand name Trazimera, at wholesale price of $80.74 per 10mg, representing a 22% discount. This medicine will be marketed on February 15th this year.

The ‘big three’ cancer drugs used to pull in around $21 billion a year, however, following the biosimilar erosion they have shown downward trend. Nevertheless, Roche has reported to be increasingly confident to overcome the losses and maintain growth.

It will be interesting to observe pricing dynamics in the US following the arrival of the lower priced competitors.

GPI has a growing footprint in pricing and market access analytics through our GPI pulse™ platform which is a revolutionary platform that captures real-time global pricing data and reimbursement decisions across 90+ markets at a product and indication level. GPI can model pricing erosion for both biosimilars and generics

For more information around how GPI can support you to set competitive pricing for your biosimilar or generics products or combat against the launch of competitors to your originator product then please get in contact using the details below.

+44 (0) 203 874 3050

Written by:

Arieta Azariadi, Associate Consultant

Dimitra Sotou, Senior Consultant